Published in Acta Paediatr Suppl on September 01, 1995
Understanding and meeting the needs of those using growth hormone injection devices. BMC Endocr Disord (2006) 1.28
Pharmacokinetics of recombinant human growth hormone administered by cool.click 2, a new needle-free device, compared with subcutaneous administration using a conventional syringe and needle. BMC Clin Pharmacol (2007) 0.89
Treatment adherence with the easypod™ growth hormone electronic auto-injector and patient acceptance: survey results from 824 children and their parents. BMC Endocr Disord (2011) 0.86
Results from an international multicenter trial evaluating the ease-of-use of and preference for a newly developed disposable injection pen for the treatment of growth hormone deficiency in treatment-naïve children and adults. Med Devices (Auckl) (2014) 0.75
Adherence in children with growth hormone deficiency treated with r-hGH and the easypod™ device. J Endocrinol Invest (2016) 0.75
Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet (2000) 4.34
Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med (1996) 3.73
Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut (1991) 2.98
Premature mortality due to cardiovascular disease in hypopituitarism. Lancet (1990) 2.92
Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab (2008) 2.74
Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci U S A (2001) 2.35
Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab (1997) 2.31
Growth hormone and bone. Endocr Rev (1998) 2.28
Fertility and pregnancy outcome in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hum Reprod (2008) 2.19
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med (2000) 2.16
Child health, developmental plasticity, and epigenetic programming. Endocr Rev (2010) 2.15
Growth in full-term small-for-gestational-age infants: from birth to final height. Pediatr Res (1995) 2.08
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet (2001) 2.08
Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Study. J Clin Endocrinol Metab (1999) 2.07
ESPE/LWPES consensus statement on diabetic ketoacidosis in children and adolescents. Arch Dis Child (2004) 2.01
Population-based body mass index reference values from Göteborg, sweden: birth to 18 years of age. Acta Paediatr (2000) 1.92
Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab (1998) 1.89
Body mass index reference values (mean and SD) for Swedish children. Acta Paediatr (2001) 1.88
Ghrelin stimulates gastric emptying and hunger in normal-weight humans. J Clin Endocrinol Metab (2006) 1.81
Transsphenoidal resection in Cushing's disease: undetectable serum cortisol as the definition of successful treatment. Clin Endocrinol (Oxf) (1993) 1.69
Androgen secreting adrenocortical tumours. Arch Dis Child (1999) 1.67
The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Incidences of different clinical presentations and eye complications. Arthritis Rheum (1981) 1.65
Giant cell arteritis. Clinical features and involvement of different organs. Scand J Rheumatol (1978) 1.63
Management of the child born small for gestational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society. J Clin Endocrinol Metab (2007) 1.61
Disappearing hyperdense middle cerebral artery sign in ischaemic stroke patients treated with intravenous thrombolysis: clinical course and prognostic significance. J Neurol Neurosurg Psychiatry (2008) 1.60
Long-term corticosteroid treatment in giant cell arteritis. Acta Med Scand (1986) 1.57
Protracted diarrhoea of infancy: evidence in support of an autoimmune variant. Br Med J (Clin Res Ed) (1986) 1.55
Clinical and endocrine features and long-term outcome of Graves' disease in early childhood. J Endocrinol Invest (2007) 1.54
Giant cell arteritis as a cause of death. Report of nine cases. JAMA (1986) 1.54
Daily subcutaneous administration of human growth hormone in growth hormone deficient children. Acta Paediatr Scand (1986) 1.53
Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh) (1993) 1.53
Remission induced by an elemental diet in small bowel Crohn's disease. Arch Dis Child (1987) 1.53
Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J Clin Endocrinol Metab (1996) 1.50
Early growth is not increased in untreated moderately severe 21-hydroxylase deficiency. Acta Paediatr (1995) 1.49
A homozygous splice site mutation affecting the intracellular domain of the growth hormone (GH) receptor resulting in Laron syndrome with elevated GH-binding protein. J Clin Endocrinol Metab (1996) 1.49
Different responses of bone alkaline phosphatase isoforms during recombinant insulin-like growth factor-I (IGF-I) and during growth hormone therapy in adults with growth hormone deficiency. J Bone Miner Res (1997) 1.47
Two years of growth hormone (GH) treatment increase isometric and isokinetic muscle strength in GH-deficient adults. J Clin Endocrinol Metab (1997) 1.47
The effect of cessation of growth hormone (GH) therapy on bone mineral accretion in GH-deficient adolescents at the completion of linear growth. J Clin Endocrinol Metab (2003) 1.44
Growth hormone and the metabolic syndrome. J Endocrinol Invest (1999) 1.44
Growth hormone status in six children with fetal alcohol syndrome. Acta Paediatr (1996) 1.42
Growth hormone deficiency and replacement in elderly hypopituitary adults. KIMS Study Group and the KIMS International Board. Pharmacia and Upjohn International Metabolic Database. Clin Endocrinol (Oxf) (2000) 1.41
Identification of olfactory dysfunction in carriers of X-linked Kallmann's syndrome. Clin Endocrinol (Oxf) (1994) 1.39
Circadian cortisol rhythms in healthy boys and girls: relationship with age, growth, body composition, and pubertal development. J Clin Endocrinol Metab (1997) 1.39
22-kD growth hormone exclusion assay: a new approach to measurement of non-22-kD growth hormone isoforms in human blood. Eur J Endocrinol (1996) 1.38
Bilateral testicular tumours in congenital adrenal hyperplasia: a continuing diagnostic and therapeutic dilemma. Clin Endocrinol (Oxf) (1989) 1.38
Plasma digoxin concentrations and urinary excretion during a 'simpler' regimen of infant digitalization. Arch Dis Child (1975) 1.38
Giant cell arteritis. Acta Med Scand Suppl (1982) 1.37
The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. . J Bone Miner Res (2001) 1.32
Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol (Oxf) (1994) 1.29
Prognosis of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. A follow-up study on ninety patients treated with corticosteroids. Acta Med Scand (1981) 1.27
Idiopathic short stature: definition, epidemiology, and diagnostic evaluation. Growth Horm IGF Res (2008) 1.26
Plasma pattern of immunoreactive ACTH in normal man and in patients with Nelson's syndrome. Acta Endocrinol (Copenh) (1981) 1.25
Serum levels of immunoglobulin and complement in giant-cell arteritis. JAMA (1976) 1.24
Serum levels of insulin-like growth factor I (IGF-I) and IGF binding protein 3 reflect spontaneous growth hormone secretion. J Clin Endocrinol Metab (1993) 1.24
Target height as predicted by parental heights in a population-based study. Pediatr Res (1998) 1.23
Maternal varicella infection as a cause of fetal malformations. Lancet (1973) 1.22
Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisited. J Clin Endocrinol Metab (1995) 1.21
Thrombokinetics in giant cell arteritis, with special reference to corticosteroid therapy. Ann Rheum Dis (1979) 1.21
Improved final height in girls with Turner's syndrome treated with growth hormone and oxandrolone. J Clin Endocrinol Metab (1996) 1.20
Insulin-like growth factor I gene deletion causing intrauterine growth retardation and severe short stature. Acta Paediatr Suppl (1997) 1.19
Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab (1998) 1.19
Assimilation of triglycerides in subcutaneous and intraabdominal adipose tissues in vivo in men: effects of testosterone. J Clin Endocrinol Metab (1996) 1.18
Embryology of the adrenal glands and its relevance to diagnostic imaging. Clin Radiol (2005) 1.15
Specific autoantibodies to gut epithelium in two infants with severe protracted diarrhoea. J Pediatr Gastroenterol Nutr (1985) 1.15
Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. Arterioscler Thromb (1993) 1.14
Acceleration of linear growth following intestinal resection for Crohn disease. Eur J Pediatr (1990) 1.14
Epidemiology and mortality in 220 patients with polymyalgia rheumatica. Br J Rheumatol (1995) 1.11
Body composition in young adult survivors of childhood acute lymphoblastic leukaemia. Eur J Endocrinol (2005) 1.11
GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clin Endocrinol (Oxf) (1999) 1.11
Reference values for height, height velocity and weight in Turner's syndrome. Swedish Study Group for GH treatment. Acta Paediatr (1997) 1.10
Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab (2004) 1.10
Altered lipid pattern explains increased cardiovascular mortality in hypopituitary patients with growth hormone deficiency. Clin Endocrinol (Oxf) (1998) 1.10
Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh) (1993) 1.09
Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol (1997) 1.09
Premature death in patients operated on for primary hyperparathyroidism. World J Surg (1991) 1.08
Long-term survival in giant cell arteritis including temporal arteritis and polymyalgia rheumatica. A follow-up study of 90 patients treated with corticosteroids. Acta Med Scand (1986) 1.08
Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group. J Clin Endocrinol Metab (1997) 1.08
Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency. Eur J Endocrinol (2007) 1.07
Prediction of long-term response to recombinant human growth hormone in Turner syndrome: development and validation of mathematical models. KIGS International Board. Kabi International Growth Study. J Clin Endocrinol Metab (2000) 1.07
Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency - a worldwide patient survey. BMC Endocr Disord (2012) 1.06
Prevalence trends of obesity and overweight among 10-year-old children in western Sweden and relationship with parental body mass index. Acta Paediatr (2004) 1.06
Sympathetic neural burst amplitude distribution: A more specific indicator of sympathoexcitation in human heart failure. Circulation (2000) 1.06
Decreased psychological well-being in adult patients with growth hormone deficiency. Clin Endocrinol (Oxf) (1994) 1.06
Assessment of the reliability of school nurse height measurements in an inner-city population. (The Hackney Growth Initiative). Child Care Health Dev (1993) 1.06
Inhibition of cortisol secretion by dexamethasone in relation to body fat distribution: a dose-response study. Obes Res (1996) 1.06
Detection of growth hormone abuse in sport. Growth Horm IGF Res (2007) 1.05
Comparisons in the epidemiology, diagnostic features and cure rate by transsphenoidal surgery between paediatric and adult-onset Cushing's disease. Eur J Endocrinol (2011) 1.04
Growth hormone-deficient adults are insulin-resistant. Metabolism (1995) 1.04
Delayed puberty and response to testosterone in a rat model of colitis. Am J Physiol Regul Integr Comp Physiol (2001) 1.04
Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality. J Clin Endocrinol Metab (2000) 1.04
Defects in growth hormone receptor signaling. Trends Endocrinol Metab (2007) 1.04
Altered relation between circulating levels of insulin-like growth factor-binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects. J Clin Endocrinol Metab (1995) 1.03
Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab (1997) 1.03